The new facility houses expanded in vitro and in vivo biology services, drug metabolism and pharmacokinetics (DMPK), toxicology and a vivarium.
Hyderabad: Sai Life Sciences, a Contract Research, Development & Manufacturing Organization (CRO-CDMO), opened a new discovery biology facility at its integrated R&D campus in Hyderabad.
Making the announcement, Krishna Kanumuri, CEO & MD of Sai Life Sciences, said, “The new facility marks the culmination of a journey we began two years ago, of creating differentiated value for our discovery clients through an integrated delivery model across Boston and Hyderabad. By bringing the best of talent, technology, complementary services and efficiency we are confident of bringing unique value to our clients and are keen to take on integrated discovery mandates, at scale.”
The new facility houses expanded in vitro and in vivo biology services, drug metabolism and pharmacokinetics (DMPK), toxicology and a vivarium. The facility augments both, its capabilities and capacity, to deploy cutting-edge platforms and technologies for accelerating integrated drug discovery programmes.
Sai Life Sciences has been steadily growing its biology capabilities to complement its strong foundation in medicinal chemistry, DMPK, and toxicology for supporting its customers across the entire drug discovery journey.
In 2019, the company opened its first international R&D facility with a biology lab in Boston, USA. The Boston Biology Lab is designed to offer startup and biotech companies in the region biology services to address exploratory and custom biology needs.
The company’s discovery services support a wide range of global innovator companies from startups to large pharma companies, across a diverse set of therapeutic areas including oncology, central nervous system, antivirals, and inflammation among others. Sai Life Sciences has advanced over 35 programmes to different clinical phases with the average turnaround time from hit/lead to candidate being 18 months.